Figure 10

The relationship between LUAD patients’ chemotherapeutic agents and risk model. In comparison to the low-risk group, the high-risk group was correlated to a higher sensitivity to (A) Cisplatin; (B) Docetaxel; (C) Erlotinib; (E) Paclitaxel. However, (D) Gefitinib was not significantly different between the two groups.